REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1524842
This article is part of the Research TopicImmunological Aspects and Immunotherapy in Gynecologic CancersView all 12 articles
Research Progress on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
Provisionally accepted
Wei zhang Wei zhang1,2
Yong-Min Liu Yong-Min Liu1
Yi Zhao Yi Zhao1*Dong Li Dong Li3*Shan Liu Shan Liu2Xiaojun Cai Xiaojun Cai2
ZUO ZHIGANG2Jiying Tang Jiying Tang2Xinhui Li Xinhui Li2- 1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian, Liaoning 116011, China, Dalian, China
- 2Department of Oncology, RenminHospital, Hubei University of Medicine,Shiyan, 442000 Hubei, China, Shiyan, China
- 3insitute of Clinical Medicine, RenminHospital, Hubei University of Medicine,Shiyan, 442000 Hubei, China, Shiyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded in vitro, and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.
Keywords: cervical cancer, tumor-infiltrating lymphocytes (TILs), Immunotherapy, TILs therapy, Human papillomavirus
Received: 08 Nov 2024; Accepted: 28 Apr 2025.
Copyright: © 2025 Wei zhang, Yong-Min Liu, Yi Zhao, Dong Li, Shan Liu, Xiaojun Cai, ZHIGANG, Jiying Tang and Xinhui Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yi Zhao Yi Zhao, Department of Oncology, The First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian, Liaoning 116011, China, Dalian, China
Dong Li Dong Li, insitute of Clinical Medicine, RenminHospital, Hubei University of Medicine,Shiyan, 442000 Hubei, China, Shiyan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.